Bessemer Group Inc. Has $22.21 Million Stock Holdings in Prestige Consumer Healthcare Inc. $PBH

Bessemer Group Inc. grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 20.9% in the first quarter, HoldingsChannel.com reports. The fund owned 374,691 shares of the company’s stock after acquiring an additional 64,760 shares during the quarter. Bessemer Group Inc.’s holdings in Prestige Consumer Healthcare were worth $22,207,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Norges Bank bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth $36,954,000. Nordea Investment Management AB lifted its position in Prestige Consumer Healthcare by 547.4% during the fourth quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock worth $37,811,000 after purchasing an additional 520,186 shares during the period. Brandes Investment Partners LP lifted its position in Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after purchasing an additional 292,744 shares during the period. Capital Research Global Investors grew its stake in Prestige Consumer Healthcare by 107.9% during the fourth quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock worth $34,639,000 after buying an additional 291,425 shares in the last quarter. Finally, Squarepoint Ops LLC grew its stake in Prestige Consumer Healthcare by 316.1% during the third quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock worth $18,836,000 after buying an additional 229,311 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 1.50% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.3%

NYSE PBH opened at $49.92 on Friday. The company has a market cap of $2.36 billion, a price-to-earnings ratio of 12.77, a price-to-earnings-growth ratio of 1.60 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $77.45. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The business’s fifty day moving average is $47.91 and its 200 day moving average is $57.35.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on PBH. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Finally, Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Hold” and an average target price of $70.75.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).